StoneX Group’s Matinas BioPharma MTNB Stock Holding History

StoneX Group’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-278	Closed	-$8.84K	–	618
2022 Q3	$8.84K	Buy	+278	New	+$10.9K	﹤0.01%	302

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

StoneX Group's MTNB Position: Q4 2022 in Review

StoneX Group sold out of Matinas BioPharma (MTNB) in Q4 2022, closing a stake of 278 shares — an estimated $8.84K sold.

StoneX Group first reported a position in MTNB in Q3 2022 and held it in 1 quarter. The position peaked at $8.84K in Q3 2022. 57 funds tracked by Wall St. Rank hold MTNB as of Q4 2022.

StoneX Group reported no remaining Matinas BioPharma position as of Q4 2022 after selling out during the quarter.
StoneX Group sold 278 Matinas BioPharma shares in Q4 2022, an estimated $8.84K.
StoneX Group first reported a position in Matinas BioPharma in Q3 2022 and held it in 1 quarter.
StoneX Group's Matinas BioPharma position peaked at $8.84K in Q3 2022.
57 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2022.

Based on StoneX Group's 13F filing for Q4 2022, filed 10 Feb 2023.